SLC5A2 and cardiac hypertrophy: In Dahl salt-sensitive (DS) obese rats, treatment with the SGLT2 inhibitor ipragliflozin effectively reduced cardiac hypertrophy and concurrently suppressed miR-222-3p expression [46].